AstraZeneca Resumes U.K. Clinical Trials of Its Coronavirus Vaccine After a Safety Pause
Less than a week after investors learned that AstraZeneca (NYSE: AZN) had paused the clinical trials testing its coronavirus vaccine, AZD1222, the U.K.'s Medicines Health Regulatory Authority (MHRA) determined it was safe for the company to restart the studies.
The pause was triggered by an adverse event -- clinical-trial speak for a potential side effect -- in one participant in the clinical trial. Pauses, which are fairly common in large clinical trials, give companies time to determine if the adverse event was caused by the vaccine. An independent committee for the U.K. studies reviewed the data and recommended to the MHRA that the clinical trials were safe to resume.
Image source: Getty Images.
Source Fool.com
